Introduction {#s1}
============

Osteoporosis, characterized by bone mass reduction and microarchitectural deterioration of bone issue, has become a global public health concern worldwide ([@B7]). Prevalence of osteoporosis in China has significantly increased over the past decade, from 14.94% before 2008 to 27.96% between 2012 and 2015 ([@B6]). This number is elevated for individuals of both genders above 50 years of age (34.65%), with postmenopausal osteoporosis being the most significant contributor ([@B43]; [@B6]). Postmenopausal osteoporotic can lead to hip, spine, wrist, and other fractures. These fractures significantly affect quality of life, work ability, and daily activities, and also increase financial burden through higher healthcare expenditure. Around 2.3 million osteoporotic fractures occurred in China in 2010 among people aged ≥ 50 years, costing US\$9.5 billion; both the number and costs of osteoporosis-related fractures are estimated to double by 2035, reaching 6 million fractures costing US\$25.4 billion by 2050 ([@B37]; [@B21]).

A wide range of pharmacological treatments, such as commonly used bisphosphonates, have been shown to be effective in preventing osteoporotic fractures ([@B8]; [@B40]). However, effectiveness of oral alendronate is greatly reduced by poor persistence and compliance. Non-persistence, for example, happens commonly occurs between 42.5% and 80% of patients within 6 months ([@B12]; [@B35]; [@B2]).

Zoledronic acid, once-yearly intravenous infusion, has become a popular alternative to oral alendronate for treating osteoporosis in postmenopausal women. Although systematic reviews with meta-analyses have shown zoledronic and alendronate to have similar efficiency on the reductions in the risks of different types of fractures ([@B30]; [@B48]), there may exist a trade-off under investigation---zoledronic has a greater annual cost than alendronate but has also higher rates of persistence and compliance ([@B44]). While there are reports of zoledronic being a cost-effective treatment, they were conducted with Caucasian populations ([@B1]; [@B16]). Difference in epidemiology of osteoporotic fractures and healthcare system could render those results non-applicable in China.

To our knowledge, the economic value of zoledronic has not been assessed for Chinese women with postmenopausal osteoporosis. The current research aimed to analyse the pharmacoeconomic information of zoledronic acid compared to alendronate in Chinese postmenopausal women. The secondary aim of the study was to quantify the impact of medication persistence and compliance on economic evaluation.

Methods {#s2}
=======

Overview {#s2_1}
--------

The reporting of this current research followed the recommendations for the conduct of economic evaluations in osteoporosis ([@B15]). A Markov microsimulation model was previously built and validated to evaluate the cost-effectiveness of osteoporosis management in Japan and in the USA by one of our authors ([@B26]; [@B27]; [@B28]). The model was recently updated to compare the cost-effectiveness of zoledronic acid with alendronate in Chinese postmenopausal osteoporotic women with no fracture history at different ages of group initiation. The primary end point of this study was the incremental cost-effectiveness ratios (ICERs) expressed as cost per quality-adjusted life-years (QALYs) for one strategy compared with the other. The model aimed to simulate the entire lifetime of participants (up to 105 years old or until death) to capture relevant costs and consequences of fractures experienced during the treatment period. We estimated the cost-effectiveness from health care payer (only including direct medical costs) perspective. Costs and QALYs were discounted at an annual rate of 3% according to China Guidelines for Pharmacoeconomic Evaluations ([@B22]). Three times the per capita gross domestic product (GDP) value of China in 2018 (\$29,340) was used as the willingness-to-pay (WTP) threshold. The economic modeling was developed in TreeAge Pro 2018 Software.

Model Structure {#s2_2}
---------------

The simplified representation of the model structure is shown in [**Figure 1**](#f1){ref-type="fig"}. The individual begins the path in the "no fracture" state, and movement between states based on the transition probabilities already assigned. If a participant sustains a wrist or other osteoporotic fracture (i.e., humerus, distal forearm other than wrist, tibia/fibula, pelvis, or femur other than hip), corresponding one-time cost and disutility are assigned based on the Markov state the participant resides in. Tracker variables were created to record the number of each fracture type to adjust transition probabilities, costs, and utilities to reflect the impact of prior fractures. The length of a cycle in the model is 1 year as events rarely occur more than once a year ([@B26]; [@B27]; [@B28]). A participant can sustain only one fracture per cycle. A participant can have a maximum of two hip fractures but unlimited clinical vertebral, wrist, and other osteoporotic fractures over the entire time horizon. [**Table 1**](#T1){ref-type="table"} shows the key parameters used in the health economics model.

![Structure of the osteoporosis state-transition model. Every participant starts the model in the "no fracture" state and transitions between health states or remains in the same states based on the assigned transition probabilities. Fx, Fracture.](fphar-11-00456-g001){#f1}

###### 

Summary of key parameters in the model.

  Parameter                                                                                      Value           Range                Distribution   Reference
  ---------------------------------------------------------------------------------------------- --------------- -------------------- -------------- ------------------
  Alendronate therapy                                                                                                                                
   Relative risk of hip fracture                                                                 0.45            0.27--0.68           Beta           ([@B30])
   Relative risk of clinical vertebral fracture                                                  0.50            0.33--0.79           Beta           ([@B30])
   Relative risk of wrist fracture                                                               0.50            0.34--0.73           Beta           ([@B46])
   Relative risk of other fracture                                                               0.78            0.66--0.92           Beta           ([@B30])
   Persistence rate                                                                              0.57 (year 1)   N/A                  N/A            ([@B17])
   Compliance                                                                                    0.71 (year 1)   N/A                  N/A            ([@B26])
  Zoledronic acid therapy                                                                                                                            
   Relative risk of hip fracture                                                                 0.50            0.34--0.73           Beta           ([@B30])
   Relative risk of clinical vertebral fracture                                                  0.35            0.20--0.64           Beta           ([@B30])
   Relative risk of wrist fracture                                                               0.75            0.64--0.87           Beta           ([@B26])
   Relative risk of other fracture                                                               0.69            0.55--0.84           Beta           ([@B30])
   Persistence rate                                                                              0.73 (year 2)   N/A                  N/A            ([@B44])
  Costs (2018 US dollars)                                                                                                                            
   Annual cost for Alendronate                                                                   761.64          533.15--990.13       Triangular     ([@B31])
   Annual cost for Zoledronic acid                                                               818.50          572.95--1,064.05     Triangular     ([@B31])
   Hip fracture, direct costs                                                                    7103.25         4972.28--9,234.23    Triangular     ([@B34])
   Clinical vertebral fracture, direct costs                                                     1,310.11        917.08--1,703.14     Triangular     ([@B34])
   Wrist fracture, direct costs                                                                  967.34          677.14--1,257.54     Triangular     ([@B34])
   Other fracture, direct costs                                                                  1,692.41        1,184.69--2,200.13   Triangular     ([@B34])
   Annual cost for the post-hip fracture                                                         4,438.08        3,106.66--5,769.50   Triangular     ([@B38])
   DXA scan                                                                                      85              59.5--110.5          Triangular     ([@B31])
   Blood test                                                                                    72              50.4--93.6           Triangular     ([@B31])
   Physician visit                                                                               10              7--13                Triangular     ([@B31])
  Utilities                                                                                                                                          
   Age 65-69                                                                                     0.806           0.765--0.846         Beta           ([@B42])
   Age 70-74                                                                                     0.747           0.709--0.784         Beta           ([@B42])
   Age 75-79                                                                                     0.731           0.694--0.767         Beta           ([@B42])
   Age 80-84                                                                                     0.699           0.664--0.733         Beta           ([@B42])
   Age 85+                                                                                       0.676           0.642--0.709         Beta           ([@B42])
   Hip fracture, first year(multiplier)                                                          0.776           0.720--0.844         Beta           ([@B36])
   Hip fracture, subsequent year(multiplier)                                                     0.855           0.800--0.909         Beta           ([@B36])
   Clinical vertebral fracture, first year(multiplier)                                           0.724           0.667--0.779         Beta           ([@B36])
   Clinical vertebral fracture, subsequent year(multiplier)                                      0.868           0.827--0.922         Beta           ([@B36])
   Wrist fracture(multiplier)                                                                    0.940           0.910--0.960         Beta           ([@B11])
   Other fracture(multiplier)                                                                    0.910           0.880--0.940         Beta           ([@B11])
  Annual fracture incidence per 1,000 persons (without intervention)                                                                                 
   Hip fracture, age 65--69                                                                      0.96            N/A                  N/A            ([@B45])
   Hip fracture, age 70--74                                                                      2.33            N/A                  N/A            ([@B45])
   Hip fracture, age 75--79                                                                      4.08            N/A                  N/A            ([@B45])
   Hip fracture, age 80--84                                                                      6.44            N/A                  N/A            ([@B45])
   Hip fracture, age 85+                                                                         6.59            N/A                  N/A            ([@B45])
   Clinical vertebral fracture, age 65--69                                                       5.64            N/A                  N/A            ([@B3])
   Clinical vertebral fracture, age 70--74                                                       8.74            N/A                  N/A            ([@B3])
   Clinical vertebral fracture, age 75--79                                                       12.05           N/A                  N/A            ([@B3])
   Clinical vertebral fracture, age 80--84                                                       21.19           N/A                  N/A            ([@B3])
   Clinical vertebral fracture, age 85+                                                          26.89           N/A                  N/A            ([@B3])
   Wrist fracture, age 65--69                                                                    12.95           N/A                  N/A            ([@B23])
   Wrist fracture, age 70--74                                                                    13.17           N/A                  N/A            ([@B23])
   Wrist fracture, age 75--79                                                                    13.87           N/A                  N/A            ([@B23])
   Wrist fracture, age 80--84                                                                    15.01           N/A                  N/A            ([@B23])
   Wrist fracture, age 85+                                                                       15.10           N/A                  N/A            ([@B23])
   Other osteoporotic fracture, age 65--69                                                       6.60            N/A                  N/A            ([@B27])
   Other osteoporotic fracture, age 70--74                                                       9.84            N/A                  N/A            ([@B27])
   Other osteoporotic fracture, age 75--79                                                       14.44           N/A                  N/A            ([@B27])
   Other osteoporotic fracture, age 80--84                                                       18.06           N/A                  N/A            ([@B27])
   Other osteoporotic fracture, age 85+                                                          26.06           N/A                  N/A            ([@B27])
  Relative risks of fractures for individuals with osteoporosis                                                                                      
   Hip fracture, age 65--69                                                                      3.91            3.28--4.56           Gamma          ([@B18]; [@B17])
   Hip fracture, age 70--74                                                                      3.13            2.80--3.47           Gamma          ([@B18]; [@B17])
   Hip fracture, age 75--79                                                                      2.60            2.39--2.82           Gamma          ([@B18]; [@B17])
   Hip fracture, age 80--84                                                                      2.04            1.91--2.17           Gamma          ([@B18]; [@B17])
   Hip fracture, age 85+                                                                         1.92            1.78--2.05           Gamma          ([@B18]; [@B17])
   Clinical vertebral fracture, age 65--69                                                       2.59            1.19--4.27           Gamma          ([@B24]; [@B18])
   Clinical vertebral fracture, age 70--79                                                       2.15            1.15--3.15           Gamma          ([@B24]; [@B18])
   Clinical vertebral fracture, age 80+                                                          1.82            1.12--2.41           Gamma          ([@B24]; [@B18])
   Wrist fracture, age 65--69                                                                    1.78            1.78--2.19           Gamma          ([@B24]; [@B18])
   Wrist fracture, age 70--79                                                                    1.6             1.60--1.88           Gamma          ([@B24]; [@B18])
   Wrist fracture, age 80+                                                                       1.45            1.45--1.64           Gamma          ([@B24]; [@B18])
   Other osteoporotic fracture, age 65--69                                                       2.19            1.78--2.59           Gamma          ([@B24]; [@B18])
   Other osteoporotic fracture, age 70--79                                                       1.88            1.60--2.15           Gamma          ([@B24]; [@B18])
   Other osteoporotic fracture, age 80+                                                          1.64            1.45--1.82           Gamma          ([@B24]; [@B18])
  Annual mortality rate                                                                                                                              
   65--69                                                                                        0.01031         N/A                  N/A            ([@B38])
   70--74                                                                                        0.02036         N/A                  N/A            ([@B38])
   75--79                                                                                        0.03784         N/A                  N/A            ([@B38])
   80--84                                                                                        0.06998         N/A                  N/A            ([@B38])
   85+                                                                                           0.13603         N/A                  N/A            ([@B38])
  Excess mortality after a hip fracture                                                                                                              
   Relative hazard for mortality within a year after a hip fracture                              2.87            2.52--3.27           N/A            ([@B10])
   Relative hazard for mortality for second and beyond after a hip fracture                      1.73            1.56--1.90           N/A            ([@B10])
   Proportion of excess mortality after a hip fracture directly attributable to a hip fracture   0.25            N/A                  N/A            ([@B19])
  Discounts                                                                                                                                          
   Costs                                                                                         0.03            0--0.05              Triangular     ([@B22])
   Effectiveness                                                                                 0.03            0--0.05              Triangular     ([@B22])

Fracture Probabilities and Mortality {#s2_3}
------------------------------------

Annual hip and clinical vertebral fracture rates were based on recent epidemiological studies in the Chinese population ([@B3]; [@B45]). As incidence rates of wrist and other osteoporotic fractures are unavailable in the Chinese context, data were retrieved from papers in the USA and Norway ([@B25]; [@B23]). To accurately reflect the fracture risks of women with osteoporosis, the estimated values were adjusted using a method described in the previous works of one of our authors ([@B26]; [@B27]; [@B28]). The method calculated the relative risk of individuals below the threshold value (i.e. BMD T-score≤-2.5) compared with that of the general population ([@B18]).

The age-specific background mortality rates were retrieved from the China Public Health Statistical Yearbook ([@B32]). As described in the previous study, excess mortality was assumed following the hip fracture events ([@B10]). It is assumed that hip fracture events only contributed to 25% of the excess mortality, as comorbidities seem to play an important role ([@B19]). No excess mortality was associated with clinical vertebral fractures ([@B26]; [@B27]; [@B28]).

Treatment {#s2_4}
---------

Zoledronic acid strategy comprised 3 years of zoledronic acid at a dosage of 5 mg per year and alendronate strategy consisted of once-weekly oral alendronate therapy at a dosage of 70 mg per week. The relative risks of fractures on different treatments were obtained from the recent network meta-analysis ([@B9]). It was assumed that relative reductions of treatment were identical regardless of age and there was no difference in effectiveness between generic and brand-name medicines. It was also assumed that participants undergoing therapy went through a physician visit, dual-energy X-ray absorptiometry (DXA), and blood test per year, as recommended by the Chinese guidelines for the diagnosis and treatment of primary osteoporosis ([@B47]).

Persistence and compliance during the medical treatment were considered in our research ([@B41]; [@B14]). A higher compliance rates in the clinical therapy of oral alendronate than observational studies that reflected actual real world setting. The impact of their difference was included into the economic model by presuming a linear regression to assess relationship between the relative risk reduction and treatment compliance ([@B26]; [@B27]; [@B28]). Additionally, the residual benefits on fracture risk for those who discontinue treatment were considered, known as the offset-time effect. For those who discontinued therapy, no treatment effect was received and offset-time was assumed to be equal to the duration of their treatment period ([@B13]).

Costs {#s2_5}
-----

Direct medical costs included the costs of drugs, fracture-related treatments, physician visits, DXA scans, blood testings, and long-term care costs associated with hip fracture. All costs were converted to 2018 USD using the web-based currency converter ([@B4]).

The costs of alendronate and zoledronic acid were based on different brand prices and their respective market share in China. Medication costs were assumed to be proportional to their compliance and persistence with treatments (i.e., assuming compliance of alendronate therapy is 71% in the first year, the estimation of annual cost for alendronate is \$761.64 × 0.71 in the first year). For individuals who discontinued alendronate within the first year, a 6-month fee was charged. We also included the medical expense for intravenous injection and the prevention of influenza-like symptoms into the expense of zoledronic acid.

Medical costs of the first year following fracture and annual long-term care costs for the "post-hip fracture" state were derived from previously published studies in Chinese setting ([@B34]; [@B38]). Costs of physician visits, DXA scans, blood testings, and long-term care costs were sourced from the health system or the National Development and Reform Commission of China ([@B31]).

Utilities {#s2_6}
---------

Age-and sex-specific baseline health state utility values for those without osteoporotic fractures were obtained from the Chinese National Health Services Survey ([@B42]). We considered the relative reductions of utility attributable to the hip or clinical vertebral fractures, and the proportionate effects of a fracture on utility values in the first and subsequent year were derived from a recent meta-analysis ([@B36]). Other osteoporotic fractures were assumed to only have a decreased risk of utility in the first year. ([@B11]).

### Model Simulation and Sensitivity Analysis {#s2_6_1}

For base case analyses, we ran the model with 100,000 iterations (100,000 individuals through the model one at a time) for individuals ages 65, 70, 75, and 80. Deterministic (one-way) sensitivity analyses were conducted by varying each key model parameter, while keeping all other variables constant at their base case values, over a range of values derived from 95% confidence intervals or the range informed in the relevant article. Probabilistic sensitivity analyses were performed to assess the effects of uncertainty in key model parameters simultaneously using Monte-Carlo simulations. In this method, all parameters were randomly drawn for 1,000 iterations from distributions of their probabilities and 10,000 trials per simulation. Three scenario analyses were carried out: (A) the patients with full persistence, (B) the patients with full compliance, and (C) the patients with both full persistence and full compliance.

Results {#s3}
=======

Model Validation {#s3_1}
----------------

Consistent with data in the Chinese life table ([@B32]), the economic model estimated that without intervention, the probabilities of dying by 105 years old were 99.0 (initial age 65 years), 98.8 (initial age 70 years), 98.5 (initial age 75 and 80 years), respectively. The model also predicted that without intervention, the lifetime probabilities of women experiencing at least one hip fracture or one clinical vertebral fracture by 65 years old were 11.099% and 39.693%, respectively, consistent with epidemiological data in China ([@B47]).

Base Case Analysis {#s3_2}
------------------

In the base case for postmenopausal osteoporotic women, the mean incremental costs and QALYs for zoledronic acid instead of alendronate were \$1,014 and 0.043, \$851 and 0.049, \$824 and 0.056, and \$718 and 0.059 at ages 65, 70, 75, and 80, respectively. The ICERs for the zoledronic acid versus alendronate were per QALY: \$23,581 at age 65 years, \$17,367 at age 70 years, \$14,714 at age 75 years, and \$12,169 at age 80 years, respectively. Compared with the alendronate strategy, the net monetary benefit (NMB) value of zoledronic acid ranged from 247.62 to 1,013.06, and the net health benefit (NHB) from 0.008 to 0.035 at different ages ([**Table 2**](#T2){ref-type="table"}).

###### 

Base case results at various ages of therapy initiation.

                     Cost (2018 USD)   ΔC      Effectiveness (QALYs)   ΔE      ICER (USD/QALY gained)   NMB        NHB
  ------------------ ----------------- ------- ----------------------- ------- ------------------------ ---------- -------
  Aged 65 years                                                                                                    
   Alendronate       10,572                    12.755                                                              
   Zoledronic acid   11,586            1,014   12.798                  0.043   23,581                   247.62     0.008
  Aged 70 years                                                                                                    
   Alendronate       9,067                     9.731                                                               
   Zoledronic acid   9,918             851     9.780                   0.049   17,367                   586.66     0.020
  Aged 75 years                                                                                                    
   Alendronate       7,245                     7.329                                                               
   Zoledronic acid   8,069             824     7.385                   0.056   14,714                   819.04     0.028
  Aged 80 years                                                                                                    
   Alendronate       5,800                     5.412                                                               
   Zoledronic acid   6,518             718     5.471                   0.059   12,169                   1,013.06   0.035

ICER, incremental cost-effectiveness ratio; NHB, net health benefit; NMB, net monetary benefit; QALYs, quality-adjusted life years; USD, United states Dollars; ΔC, incremental costs; ΔE, incremental effectiveness.

Deterministic Sensitivity Analysis {#s3_3}
----------------------------------

The results of deterministic sensitivity analysis were illustrated as tornado plots showing the influences of extreme variations in each important parameter ([**Figure 2**](#f2){ref-type="fig"} and [**Supplemental Figures 1A--C**](#SM1){ref-type="supplementary-material"}). Regardless of the starting ages, the study demonstrated that the two most impactful parameters were the annual cost of zoledronic acid and relative risk of hip fracture with zoledronic acid.

![Results of deterministic sensitivity analyses, age 80 years. Tornado diagram shows the lower and upper values for the cost effectiveness ratio of the zoledronic acid strategy to the alendronate strategy.](fphar-11-00456-g002){#f2}

Probabilistic Sensitivity Analysis {#s3_4}
----------------------------------

The results of probabilistic sensitivity analysis demonstrated that the probabilities of zoledronic acid being cost-effectiveness compared to alendronate were nearly 70, 81, 86, and 100% for starting ages 65, 70, 75, and 80 years, respectively, at a threshold of \$29,340 per QALY ([**Figure 3**](#f3){ref-type="fig"} and [**Supplemental Figures 2A--C**](#SM2){ref-type="supplementary-material"}).

![Results of probabilistic sensitivity analyses, age 80 years. The cost-effectiveness acceptability curves represent probabilities of being cost-effective achieved by the zoledronic acid strategy compared to the alendronate strategy at different willingness-to-pay (WTP) thresholds for postmenopausal osteoporotic women.](fphar-11-00456-g003){#f3}

Scenario Analysis {#s3_5}
-----------------

[**Figure 4**](#f4){ref-type="fig"} and [**Supplemental Figures 3A, B**](#SM3){ref-type="supplementary-material"} indicated the outcome of the scenario analysis considering alendronate therapy persistence and compliance. If we assumed that the patients with full persistence, the results revealed that alendronate was found to be dominant (lower costs and greater QALYs) for patients at ages 65 and 70, while zoledronic acid was more cost-effective for ages 75 and 80 years given the current WTP threshold. If we assumed that the patients with full compliance, the ICER was ranged from 8,500 USD to 16,071 USD, making zoledronic acid cost-effective with a WTP of 29,340 USD per QALY gained. If simulated populations with both full persistence and full compliance, both costs and clinical effectiveness for alendronate treatment increased except at age 80 and the cost-effectiveness decision did not change.

![The cumulative cost and effectiveness of the zoledronic acid versus oral alendronate at various ages of therapy initiation (65, 70, 75, and 80) assuming alendronate therapy with full persistence. ΔC represented the incremental costs and ΔE represented the incremental effectiveness.](fphar-11-00456-g004){#f4}

Discussion {#s4}
==========

In the current research, we evaluated the economic assessment for zoledronic acid treatment versus oral alendronate for postmenopausal osteoporotic women in China. Furthermore, we estimated the influences of alendronate persistence and compliance on clinical outcomes and costs. Base case results indicated that, compared with real-world data of alendronate, zoledronic acid therapy might be the optimal alternative option for simulated patients at all different starting ages examined at a threshold of \$29,340 per QALY from health care payer perspective. In addition, alendronate treatment was shown to be dominant for patients at ages 65 and 70 with full persistence.

To the best of our knowledge, there are four studies reporting the cost-effectiveness of zoledronic acid for the treatment of osteoporosis. Ito K constructed a Markov model to compare the cost-effectiveness of single-dose zoledronic acid and supplementation of calcium and vitamin in the USA. In the base case, routine administration of zoledronic acid for nursing home residents with osteoporosis was not a cost-effective use of resource in the USA ([@B16]). In Japan, a patient-level state-transition model was designed to assess the cost-effectiveness of zoledronic acid versus alendronate for patients with osteoporosis who had a previous vertebral fracture. In the base case, they assumed 100% treatment persistence and compliance, which is not realistic in the real world. The results demonstrated that, although zoledronic acid was dominated by alendronate (i.e., less effective and more costly), considering the advantage of high compliance and persistence, zoledronic acid appeared a cost-effective treatment option ([@B29]). Two other studies compared the cost-effectiveness of denosumab and zoledronic acid for elderly men with osteoporosis. The authors from the USA and Sweden concluded that denosumab was a cost-effective option for the treatment of elderly men ([@B33]; [@B39]).

Different methodological approaches, such as the model structure, time horizon and the measurements of costs and health utilities led to inconsistent findings of four published reports ([@B33]; [@B39]; [@B29]; [@B16]). Compared to previous pharmacoeconomic analyses, the main differences of this research are the target population and comparator. The reason we choose postmenopausal osteoporosis is mainly based on the fact that most cases of osteoporosis occur in postmenopausal women, and the incidence increases with age in China ([@B20]; [@B6]). Administration of denosumab once every 6 months was not included as this therapy for osteoporosis was not marketed in China at the time of the current research.

Poor medication persistence and compliance are common problems of osteoporosis management, and they affect both effectiveness and cost of the treatments which are the key model parameters. Compared with weekly oral alendronate, our research found that the reason why zoledronic acid was cost effective was primarily due to zoledronic acid's higher persistence rate. If we assumed that the patients had full persistence, the results revealed that alendronate was found to be dominant (i.e., lower costs and greater QALY) for patients at ages 65 and 70. It is worth noting that this heightened persistence rate of zoledronic acid was reinforced by our assumption of a residual effect from treatment; the risk for fracture returned to rates without treatment over the same years as the therapy duration in a gradual linear regression after stopping the treatment. This assumption has been consistently used in previous economic evaluations ([@B13]; [@B26]; [@B27]; [@B24]). Conversely, high compliance rate of zoledronic acid had a smaller effect than persistent rate on the results. This was mainly due to the fact that the compliance rate with weekly oral alendronate was already high.

The assumption of concurrent full persistence and compliance on the stimulated population, however, also directly increases medication costs. For example, average costs in the alendronate arm increased by 15.11% with full persistence and compliance compared with that in the base case at age 65 in the current study. While the assumption leads to overall improvements in clinical outcome, the improvement was found to be only marginal in this study. The average effectiveness with full persistence and compliance was 12.813 QALYs, which increased only by 0.45% relative to the base case. This is consistent with the previous study ([@B5]).

The results of the current economic model have to be interpreted within the context of some limitations. First, due to the heterogeneity of payer perspectives and the country-specific epidemiologic data used, our results should be conservatively generalized to women in other countries. Second, the current analysis did not take into account different osteoporosis screening strategies, which might have an impact on the cost effectiveness analysis. Third, although much of the data presented here to construct the model were obtained from Chinese data sets, some data were based on other countries, such as relative hazard for mortality after a hip fracture, proportion of excess mortality directly attributable to a hip fracture and incidence rates of wrist and other osteoporotic fractures. An updated pharmacoeconomic evaluation should be carried out when such data are available in the Chinese population. Finally, ever though we have identified for healthcare policymakers in China whether zoledronic acid treatment is of the best value for money, we have not attempted to consider issues of affordability (i.e., budget impact). This gap in research is an area for future research.

Our analysis may have several clinical and economic strengths. First, to the best of our knowledge, this is the first study to address the cost-effectiveness of zoledronic acid compared with oral alendronate based on a Chinese setting. The current study will provide valuable evidence to help health services researchers and policymakers guide policy formulation. Second, we integrated medication persistence and compliance into the health economic modeling and extensively tested how these changes in parameters have an influence on model outputs, as persistence and compliance have been considered to be important factors in economic evaluations for osteoporosis patients. Third, we used the Markov microsimulation modeling to track data separately by patient which avoids several restrictions of Markov cohort analysis that were widely used in pharmacoeconomic assessments. For example, patients with prior fractures might not be related with higher costs or probabilities subsequently in cohort model based on the "memoryless" feature. Since a microsimulation runs individual patients through the model, which fundamentally expands the researchers to be able to consider patient characteristics and prior events to affect the future values-probabilities, costs, and utilities, leading to a more realistic model and accurate results.

In conclusion, from the perspective of Chinese health care payer, once-yearly injection of zoledronic acid is estimated to be a cost-effective treatment option compared to weekly oral of alendronate for postmenopausal osteoporotic women without prior history of fracture at a threshold of 29,340 per QALY.
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